Bristol-Myers Squibb: Expansion into Alzheimer’s Disease Psychosis Treatment As A Key Growth Catalyst!

Bristol-Myers Squibb’s third quarter 2024 earnings highlight a period of robust growth and strategic advancements, albeit accompanied by challenges typical of large pharmaceutical companies. On the positive side, the company reported a noteworthy 20% revenue increase in its growth portfolio at constant currency, which now contributes to approximately half of the total revenues. This growth is supported by products with exclusivity extending into the next decade, underscoring the company’s successful pipeline development and launch of new therapies.